|
Britain's Vectura collaborates with Janssen in asthma, COPD
Reuters Janssen, a unit of Johnson & Johnson, will then use Vectura's dry powder inhaler technologies in the development of inhaled therapeutics for airways-related diseases such as asthma, a market worth in excess of $46 billion worldwide, Vectura said … Vectura Signs Global Development And Licence Deal With Janssen In Asthma … Vectura links with Janssen on asthma/COPD drug development Vectura In Deal With Johnson & Johnson's Janssen Biotech For Asthma |
View full post on asthma – Google News